Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | IMpower110: atezolizumab vs chemo in PD-L1–selected NSCLC

Here, David Spigel, MD, Sarah Cannon Research Institute, Nashville, TN, provides an interim OS analysis of the Phase III IMpower110 study (NCT02409342) of atezolizumab vs platinum-based chemotherapy as a first-line treatment in PD-L1–selected non-small cell lung cancer (NSCLC). This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.